Q-omics provides the consensus-scored FAM30A profile across patient tissues and cancer cell-line models. FAM30A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM30A is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, FAM30A RNA expression shows 15,367 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where FAM30A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM30A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM30A survival associations across molecular data types. FAM30A RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM30A RNA expression–survival associations across cancer types. High FAM30A expression shows unfavorable associations in LAML, but favorable associations in HNSC, SKCM, LUAD, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM30A RNA expression.
This table summarizes FAM30A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM30A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM30A shows lower tumor expression in COAD, READ and STAD and higher tumor expression in LUAD, KIRC and HNSC. The COAD box plot shows higher FAM30A RNA expression in normal versus tumor tissue (log2 FC = −1.302, t-test p < 0.001).
This table shows molecular features associated with FAM30A in patient tissues and cancer cell lines. In patient samples, FAM30A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM30A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
